Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines (Nasdaq: RVMD) announced that Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.
According to the company, the session will be webcast live and a replay will be available on the company's investor website for at least 14 days following the event.
Revolution Medicines (NASDAQ:RVMD) announced dosing of the first patient in the first-in-human trial RMC-5127-001 (NCT07349537), evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor.
The open-label trial will assess safety, tolerability, pharmacokinetics and preliminary antitumor activity as monotherapy and in combination in patients with RAS G12V–mutated PDAC, CRC and NSCLC. RMC-5127 is the company’s fifth disclosed mutant-selective RAS(ON) inhibitor and fourth clinical-stage program, targeting an estimated ~48,000 U.S. patients diagnosed annually with RAS G12V–driven cancers.
Revolution Medicines (Nasdaq: RVMD) announced that the U.S. FDA granted Breakthrough Therapy Designation to zoldonrasib for adults with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 therapy and platinum chemotherapy. The designation is based on data from the monotherapy cohort of the Phase 1 RMC-9805-001 trial, which demonstrated encouraging antitumor activity and acceptable safety and tolerability. Zoldonrasib is a tri-complex RAS(ON) G12D-selective covalent inhibitor that binds cyclophilin A. This is the first Breakthrough Therapy Designation for an investigational drug specifically targeting RAS G12D in NSCLC and follows prior designations for the company's daraxonrasib and elironrasib.
Revolution Medicines (Nasdaq: RVMD) said CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT.
The presentation will be available via live webcast at the company's investor events page and a replay will be posted on the website for at least 14 days after the live presentation.
Revolution Medicines (NASDAQ:RVMD) announced on Dec 18, 2025 that the first patient was randomized in RASolute 304, a global, open-label Phase 3 trial of daraxonrasib in resectable pancreatic ductal adenocarcinoma (PDAC) after surgery and perioperative chemotherapy.
RASolute 304 plans to enroll approximately 500 patients with oncogenic RAS mutations and will evaluate whether daraxonrasib improves disease-free survival versus observation; secondary endpoints include overall survival, safety, and tolerability. Daraxonrasib is being evaluated in four global Phase 3 trials, including three in PDAC and one in RAS mutant non-small cell lung cancer.
Revolution Medicines (Nasdaq: RVMD) reported Q3 2025 financial results and clinical progress on RAS(ON) inhibitors.
Clinical: RASolute 302 enrollment for daraxonrasib in previously treated PDAC is winding down with an expected data readout in 2026; RASolute 303 (first-line metastatic PDAC) remains on track to start in 2025; RASolute 304 (adjuvant resectable PDAC) has been initiated. Daraxonrasib holds FDA Breakthrough Therapy, Orphan Drug designation and a Commissioner’s National Priority Voucher. New trials for zoldonrasib, elironrasib and RMC-5127 are planned in 2026–2026 Q1.
Financial: Cash and marketable securities were $1.93B at Sept 30, 2025, including a $250M royalty tranche and $1.75B committed; Q3 R&D $262.5M, G&A $52.8M, net loss $305.2M; reiterated FY2025 GAAP net loss guidance of $1.03B–$1.09B. Company announced senior commercial and development hires and held a webcast on Nov 5, 2025.
Revolution Medicines (Nasdaq: RVMD) announced that CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will participate in two investor conference fireside chats in November 2025.
Event details: Guggenheim Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 9:00 a.m. ET, and Jefferies Global Healthcare Conference fireside chat on Tuesday, November 18, 2025 at 9:30 a.m. GMT. Live webcasts and archived replays will be available at the company investor events page, with replay access for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) will report third-quarter 2025 financial results on Wednesday, November 5, 2025 after market close.
The company said a senior management webcast will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. Investors can listen live or access the archived webcast at https://ir.revmed.com/events-and-presentations. A replay will be available on the company website for at least 14 days following the live event.
Revolution Medicines (NASDAQ: RVMD) announced on October 27, 2025 that the U.S. FDA granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer.
Daraxonrasib is a RAS(ON) multi-selective inhibitor currently being studied in a global Phase 3 RASolute 302 trial for second-line metastatic pancreatic ductal adenocarcinoma (PDAC). The company also plans two additional Phase 3 trials: one for first-line metastatic PDAC and one for adjuvant treatment in resectable PDAC.
The designation makes daraxonrasib eligible for incentives, including tax credits for clinical trial costs, exemption from certain FDA fees, and up to seven years of market exclusivity if approved.
Revolution Medicines (Nasdaq: RVMD) reported updated clinical results for elironrasib in previously treated KRAS G12C NSCLC patients who had received prior KRAS(OFF) G12C inhibitors, highlighted at the AACR-NCI-EORTC Symposium (Oct 23-25, 2025).
As of the Aug 4, 2025 cutoff (n=24), elironrasib at 200 mg BID showed a confirmed objective response rate 42% (95% CI: 22-63), disease control rate 79%, median duration of response 11.2 months, median PFS 6.2 months, and 12-month OS rate 62%. In July 2025 elironrasib received Breakthrough Therapy Designation for certain KRAS G12C NSCLC patients.